|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
Why Oral Cancer Threatens Men [Scientific American]
|
|
|
|
|
|
Researchers
link the rise of these cancers to changing sexual practices, perhaps
dating back to the 1970s. “People have more partners than they had in
the past, and they initiate oral sex at an earlier age than previous
generations did,” says Gypsyamber D'Souza.
|
|
|
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
Genetic Differences in Prostate Cancer Pinpointed in Black Men [Renal & Urology News]
|
|
|
|
|
|
A
team led by Olivier Cussenot, MD, PhD, of Tenon Hospital in Paris,
showed that prostate tumors in African-Caribbean men, compared with
those in French-Caribbean men, are characterized by a more frequent
deletion at 1q41-43 encompassing the DNA repair gene PARP1 and a greater
proportion of intrachromosomal rearrangements, including duplications
associated with CDK12 truncating mutations, the investigators reported
in European Urology.
|
|
|
|
|
|
|
4.3 Dép., diag. & prono. - Industriels
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
We can now customize cancer cures, tumor by tumor [MIT Technology Review]
|
|
|
|
|
|
The
technology for the first truly personalized cancer vaccine is not yet
proven. And these therapies are all likely to be expensive. But he
insists that if it’s all done right, the extra costs and thinner margins
will be more than offset by the sheer number of people who would use
the treatment.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
FDA Approves a New PARP Inhibitor for BRCA-mutant Breast Cancer [Cancer Research Catalyst]
|
|
|
|
|
|
The
approval of talazoparib was based on results from the randomized, phase
III EMBRACA clinical trial. The results showed that among the 287
patients who received talazoparib, the median progression-free survival
was 8.6 months. This was statistically significantly greater than the
5.6 months median progression-free survival among the 144 patients who
received cytotoxic chemotherapy.
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
5.9.1 ASTRO
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.14 Prix Nobel
|
|
|
|
6.8 Communication
|
|
|